<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676854</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-PV-M</org_study_id>
    <nct_id>NCT04676854</nct_id>
  </id_info>
  <brief_title>Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD</brief_title>
  <acronym>PRIMAvera</acronym>
  <official_title>Restoration of Central Vision With the PRIMA System in Patients With Atrophic Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pixium Vision SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pixium Vision SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of the PRIMA System in&#xD;
      patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant. The&#xD;
      subjects will be assessed with various visual function and functional vision tests at defined&#xD;
      timepoints throughout the clinical investigation with the PRIMA System (Implant and Visual&#xD;
      Processor).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">November 24, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with meaningful improvement of visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number and severity of device and procedure related serious adverse events at 12 months follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with meaningful improvement of visual acuity</measure>
    <time_frame>6, 24, 36 months</time_frame>
    <description>Proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more at 6, 24 and 36 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of visual acuity</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>Mean improvement of visual acuity at 6, 12, 24 and 36 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by IVI</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>IVI-Impact of Vision Impairment questionnaire (quality of life based on patient reported outcome of functional vision, participation in vision-related daily living activities and emotional well-being) at 6, 12, 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central visual perception</measure>
    <time_frame>12 months</time_frame>
    <description>Central visual perception with PRIMA at 12 months compared to central visual perception at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>Number and severity of procedure and device related adverse events at 6, 12, 24 and 36 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of natural visual acuity</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>Change of natural visual acuity without the PRIMA Glasses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of compliant implantations</measure>
    <time_frame>4 weeks after implantation</time_frame>
    <description>Number of subjects with PRIMA implant placed according protocol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>PRIMA Bionic Vision System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRIMA Bionic Vision System</intervention_name>
    <description>Implantation of PRIMA, Vision training, follow up</description>
    <arm_group_label>PRIMA Bionic Vision System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is 60 years or older at the date of inclusion;&#xD;
&#xD;
          -  Has a confirmed diagnosis of geographic atrophy due to AMD in both eyes;&#xD;
&#xD;
          -  The study eye has best corrected visual acuity of logMAR 1.2 (20/320) or worse as&#xD;
             measured by ETDRS test;&#xD;
&#xD;
          -  Has an atrophic patch in the study eye including the fovea of at least the implant&#xD;
             size (&gt;4.5 mm2 and &gt;2.4 mm in minimum diameter);&#xD;
&#xD;
          -  Understands the constraints of the study and accepts to present for all scheduled&#xD;
             follow-up visits;&#xD;
&#xD;
          -  Patient signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has cataract in the study eye (with LOCS III scale NO, NC, C or P&gt;1); (these patients&#xD;
             will be asked to have cataract surgery performed prior to enrollment; all other&#xD;
             patients will get IOL replacement during the PRIMA implantation);&#xD;
&#xD;
          -  Underwent intra ocular lens implantation in the study eye within the last month ;&#xD;
&#xD;
          -  Has a highly myopic study eye (&gt;26 mm AP);&#xD;
&#xD;
          -  Has a highly hyperopic study eye (&lt;20 mm AP);&#xD;
&#xD;
          -  Has no light perception in either eye;&#xD;
&#xD;
          -  Has a history of documented choroidal neovascularization in either eye;&#xD;
&#xD;
          -  Has any signs of exudative AMD including exudative AMD with detachment of retinal&#xD;
             pigment epithelium in the central visual field of the study eye;&#xD;
&#xD;
          -  Has an implanted telescope in one eye;&#xD;
&#xD;
          -  Has a black IOL in the study eye;&#xD;
&#xD;
          -  Has any disease (other than study allowed diseases) or condition that affects retinal&#xD;
             function of the study eye or the visual system (e.g., central retinal artery/vein&#xD;
             occlusion, end-stage diabetic retinopathy, Proliferative Diabetic Retinopathy (PDR),&#xD;
             diabetic macular edema (DME), severe Non-Proliferative Diabetic Retinopathy (NPDR),&#xD;
             retinal detachment, infectious or inflammatory retinal disease, severe glaucoma, optic&#xD;
             neuropathy, etc.) ;&#xD;
&#xD;
          -  Has any disease or condition that prevents adequate examination (including OCT) of the&#xD;
             study eye including, but not limited to media opacities that cannot be resolved prior&#xD;
             to implantation. Note, that this criterion is also important for the function of the&#xD;
             implant;&#xD;
&#xD;
          -  Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye;&#xD;
&#xD;
          -  Suffers from nystagmus or other ocular motility disorders;&#xD;
&#xD;
          -  Has any disease or condition that precludes the understanding or communication of the&#xD;
             informed consent, study requirements or test protocols (e.g., deafness, severe&#xD;
             multiple sclerosis, amyotrophic lateral sclerosis, severe neuritis, etc.);&#xD;
&#xD;
          -  Has epileptic seizures;&#xD;
&#xD;
          -  Has a known sensitivity to the contact materials of the implant (iridium oxide,&#xD;
             silicon-carbide and titanium);&#xD;
&#xD;
          -  Has a known allergy to anesthetic drugs;&#xD;
&#xD;
          -  Presents with hypotonia in the study eye (&lt;8 mmHg);&#xD;
&#xD;
          -  Presents with hypertonia in the study eye (&gt;23 mmHg with treatment);&#xD;
&#xD;
          -  Has active cancer or a history of intraocular, optic nerve or brain cancer and&#xD;
             metastasis;&#xD;
&#xD;
          -  Is an immune-suppressed subject (e.g., due to HIV positive diagnosis, etc.);&#xD;
&#xD;
          -  Is a known carrier of multi-resistant microorganisms;&#xD;
&#xD;
          -  Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;&#xD;
&#xD;
          -  Is participating in another investigational drug or device study that may interfere&#xD;
             with the PRIMAvera study;&#xD;
&#xD;
          -  Has a history of chronic or recurrent infection or inflammation that would preclude&#xD;
             participation in the study;&#xD;
&#xD;
          -  Has significant recurrent or chronic inflammations or infections. Specifically,&#xD;
             patients with the following disorders are excluded:&#xD;
&#xD;
               -  Severe chronic and consuming diseases that frequently associated with infection&#xD;
                  (e.g. Crohn disease, Whipple's disease);&#xD;
&#xD;
               -  Active inflammation in the area of the eye (e.g. herpes of cornea and/or&#xD;
                  conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion);&#xD;
&#xD;
          -  Has a severe psychological disorder;&#xD;
&#xD;
          -  Does not have the mental capacity to legally sign the informed consent;&#xD;
&#xD;
          -  Has severe renal, cardiac, hepatic, etc. organ diseases (ASA IV or worse);&#xD;
&#xD;
          -  Has head dimensions that are incompatible with the PRIMA Glasses;&#xD;
&#xD;
          -  Has a refraction of study eye higher than + 4 dpt or lower than - 4 dpt for patients&#xD;
             with IOL (there is no refraction criteria for phakic patients, since they get an IOL&#xD;
             during PRIMA implantation);&#xD;
&#xD;
          -  Has too high and/or unrealistic expectations (e.g., believes that a benefit is&#xD;
             guaranteed or expects normal vision after surgery).&#xD;
&#xD;
        The following additional exclusion criteria are applicable for French subjects:&#xD;
&#xD;
          -  Is a protected person per French law (e.g. is under guardianship, person deprived of&#xD;
             their liberty);&#xD;
&#xD;
          -  Is not affiliated to a mandatory social security program (health insurance).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ralf Hornig, PhD</last_name>
    <phone>+33176214742</phone>
    <email>clinical-trial@pixium-vision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Noëlle Delyfer, Prof.</last_name>
      <email>implant-retine@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Noëlle Delyfer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Korobelnik, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier intercommunal de Créteil - Service Ophtalmologie</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Souied, Prof</last_name>
      <phone>+33 1 57 02 30 16</phone>
    </contact>
    <investigator>
      <last_name>Eric Souied, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix-Rousse CHU de LYON</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33426732724</phone>
      <email>GHN_RECHERCHE_OPHTALMOLOGIE@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent KODJIKIAN, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Monticelli Paradis</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 91 16 05 84</phone>
      <email>agne.retine@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Frédéric Matonti, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Weber, Prof</last_name>
      <email>bp-ophtalmologie-traitements-innovants@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Weber, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital des Quinze Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 1 4002 14 55</phone>
    </contact>
    <investigator>
      <last_name>Girmens Jean-François, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. De Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 1 48 03 64 37</phone>
      <email>eauge@for.paris</email>
    </contact>
    <investigator>
      <last_name>Yannick LeMer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Holz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE), Augenklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Spitzer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen -Augenklinik</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>studien.augenklinik@klilu.de</email>
    </contact>
    <investigator>
      <last_name>Lars-Olof Hattenbach, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik der Ludwig-Maximilian Universität München</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 89 4400 53717</phone>
      <email>stefanie.guenther@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Siegfried Priglinger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KNAPPSCHAFTSKLINIKUM SAAR GMBH Augenklinik Sulzbach</name>
      <address>
        <city>Sulzbach/Saar</city>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6897 574 3002</phone>
      <email>studie.augen@kksaar.de</email>
    </contact>
    <investigator>
      <last_name>Boris Stanzel, PD Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+7071 29 87435</phone>
      <email>studienarzt.augenklinik@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Karl Ulrich Bartz-Schmidt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugía Ocular de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(+34)934000700</phone>
      <email>imo@imo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael Navarro, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>0207 566 2117</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>2075662283</phone>
      <email>mahi.muqit1@nhs.net</email>
    </contact>
    <contact_backup>
      <email>s.shakhmurzaeva@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Mahi Muqit, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.pixium-vision.com</url>
    <description>Pixium Vision</description>
  </link>
  <reference>
    <citation>Palanker D, Le Mer Y, Mohand-Said S, Muqit M, Sahel JA. Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration. Ophthalmology. 2020 Aug;127(8):1097-1104. doi: 10.1016/j.ophtha.2020.02.024. Epub 2020 Feb 25.</citation>
    <PMID>32249038</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

